Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson Seeks Co-Promotion Partner For Oxytrol In Primary Care Setting

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is seeking a partner with "strong relationships" with high-volume prescribers of overactive bladder therapies in the primary care market. Watson wants to retain Oxytrol's position in primary care despite the company's intention to shift its marketing focus to specialty care.

You may also be interested in...



Big Pharma Pushes Watson's Oxytrol To Specialty Area

Continued decline in sales of the overactive bladder patch reinforces Watson focus on the urologist specialty area; firm cites inadequate resources to compete with big pharma in the primary care market.

Big Pharma Pushes Watson's Oxytrol To Specialty Area

Continued decline in sales of the overactive bladder patch reinforces Watson focus on the urologist specialty area; firm cites inadequate resources to compete with big pharma in the primary care market.

Ventiv Dermatology Sales Force To Promote Ranbaxy’s Isotretinoin

The firms sign multi-year agreement to market Sotret. Ventiv says it has established a specialty dermatology sales force to promote the product.

Related Content

Topics

UsernamePublicRestriction

Register

PS060438

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel